Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old drug shows new promise against Post-Surgery fluid buildup

NCT ID NCT02799212

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a 6-day infusion of somatostatin, a drug that lowers pressure in the liver's blood vessels, could prevent ascites (fluid buildup) after liver cancer surgery. 179 patients with liver cancer and underlying liver disease took part. The goal was to see if somatostatin reduces the need for drainage or punctures for fluid removal.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
somatostatin
What this could lead to
If it works, this could offer a simple, temporary way to prevent dangerous fluid buildup after liver surgery, reducing complications and hospital stays.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely reported. The benefit may be modest or not apply to all patients, and somatostatin can cause side effects like nausea or blood sugar changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

179 people

The number who actually took part.

Started

Jan 2018

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with HCC diagnosed by histology or by imaging findings according to the Barcelona Clinic Liver Cancer Group * Patients with a single or multiple HCCs deemed to be resectable with a curative intent at the preoperative evaluation * Patients for whom an indication for hepatectomy has been decided and approved by multidisciplinary board: * by laparotomy * by coelioscopy with resection of at least 2 liver segments * Patients with any underlying liver disease with or without proven cirrhosis, regarding histological features (including F2-F3-F4 fibrosis with or without cirrhosis) or with other evidence of a diseased liver if no biopsy has been performed preoperatively (dysmorphic liver or evidence of portal hypertension at imaging findings, oesophageal varices at endoscopy) * Age ≥ 18 years * Patients with ability to understand and sign a written inform consent form * Patients who will be available for follow-up Exclusion Criteria: * Patients participating in another interventional research in progress or including an exclusion period still in progress at pre-inclusion (except interventional research with minimal risks and constraints that do not interfere with the judgement criteria of the study according to the judgement of the coordinating investigator). * Patients with evidence of a healthy liver at biopsy Disease-associated non-inclusion criteria include: * Another histologic type of hepatic tumor besides HCC * Distant extra-hepatic metastases, including peritoneal carcinomatosis * The existence of complete portal thrombosis of the main portal trunk Operative technique-associated non-inclusion criteria include: \- Indication of coelioscopy with resection of less than 2 liver segments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ascites hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • APHM - Hôpital de la Timone

    Marseille, France

  • APHP - Hôpital Beaujon

    Clichy, France

  • CHRU Lille - Hopital Huriez

    Lille, France

  • CHU Rennes - Hôpital Pontchaillou

    Rennes, France

  • CHU de Bordeaux - Hôpital Haut Lévèque

    Pessac, France

  • CHU de Toulouse - Hopital Rangueil

    Toulouse, France

  • Hospices Civils de Lyon - Hôpital de la Croix Rousse

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.